Immatics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immatics and other ETFs, options, and stocks.About IMTX
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics.
CEOHarpreet Singh-Jasuja
CEOHarpreet Singh-Jasuja
Employees407
Employees407
HeadquartersTuebingen, Baden Wuerttemberg
HeadquartersTuebingen, Baden Wuerttemberg
Founded2020
Founded2020
Employees407
Employees407
IMTX Key Statistics
Market cap1.23B
Market cap1.23B
Price-Earnings ratio-4.66
Price-Earnings ratio-4.66
Dividend yield—
Dividend yield—
Average volume465.47K
Average volume465.47K
High today$9.56
High today$9.56
Low today$8.92
Low today$8.92
Open price$9.05
Open price$9.05
Volume1.59M
Volume1.59M
52 Week high$12.41
52 Week high$12.41
52 Week low$5.05
52 Week low$5.05
Stock Snapshot
The current Immatics(IMTX) stock price is $9.20, with a market capitalization of 1.23B. The stock trades at a price-to-earnings (P/E) ratio of -4.66.
On 2026-07-30, Immatics(IMTX) stock moved within a range of $8.92 to $9.56. With shares now at $9.20, the stock is trading +3.1% above its intraday low and -3.8% below the session's peak.
Trading activity shows a volume of 1.59M, compared to an average daily volume of 465.47K.
The stock's 52-week range extends from a low of $5.05 to a high of $12.41.
The stock's 52-week range extends from a low of $5.05 to a high of $12.41.
Analyst ratings
100%
of 11 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own IMTX. This list is generated using Robinhood data, and it’s not a recommendation.